Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ (1989) . Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem 52: 1655-1658. Adler CM, Elman I, Weisenfeld N, Kestler L, Pickar D, Breier A (2000) . Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology 22: 545-550. Kalivas PW, Richardson-Carlson R, Van Orden G (1986) . Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biol Psychiatry 21: 939-950. Laruelle M, Abi-Dargham A (1999 (Steffens et al, 2008) and white matter hyperintensity (WMH) volumes, supporting theories that these genes also have a role in LLD. The notion that WMHs are vascular in nature led our group to explore relationships between WMH volume and genes associated with systemic vascular risk. These include renin-angiotensin system genes, such as the angiotensin II receptor, vascular types 1 and 2 (AGTR1 and AGTR2) genes. In addition to reports linking AGTR1 polymorphisms to LLD outcomes, we have also found genderspecific associations between AGTR polymorphisms and WMH progression (Taylor et al, 2009) . Similarly, the methylenetetrahydrofolate reductase (MTHFR) gene, another vascular risk gene associated with folate and homocysteine metabolism, may be associated with LLD, and we are examining MTHFR and other genes related to folate metabolism in the occurrence of white matter lesions in LLD. Our studies continue to examine the role of vascular risk genes in LLD, focusing on their influence on brain structure and cognition.
Consistent with the vascular depression hypothesis is the notion the LLD is associated with disruption in frontalstriatal circuitry. These abnormalities in the prefrontal cortex, striatum, and frontal-striatal white matter tracks are also likely related to genetic differences. A previous study noted a link between the 5HTTLPR short allele and caudate volume in LLD. We recently reported an interaction between two genes, COMT (catechol-O-methyltransferase) and MTHFR, and putamen volume reduction in LLD (Pan et al, 2009) . Identification of genes associated with prefrontal cortical structure and function remains an active area of inquiry.
Beyond the vascular depression hypothesis, another avenue of genetic/neuroimaging LLD research examines the observed link between depression and later dementia. The hippocampus is a key structure related to both LLD pathophysiology and increased dementia risk. The APOE gene is associated with both depression and Alzheimer's disease, and APOE genotype has been associated with specific shape differences in geriatric depression (Qiu et al, 2009 ). Allelic differences in the 5HTTLPR gene have also been associated with hippocampal volume in LLD by several groups.
Advances in both neuroimaging technologies and genetic assessment allow us to investigate the pathophysiology of affective disorders. Existing paradigms of vascular depression and depression as dementia risk make LLD ideally suited for future genetic/imaging studies. Psychiatric genetics has turned a cornerFincreasingly robust findings can be placed in a neurobiological context, with practical implications for understanding disease pathogenesis and developing of therapeutics. A milestone in this effort was the discovery of the DISC1 (disrupted in Schizophrenia 1) gene, found via analysis of a large Scottish family with a high rate of schizophrenia and psychotic affective disorder. All affected members of the family carry a (1;11)(q42.1; q14.3) translocation; the chromosome 1 translocation break point falls between exon 8 and 9 of DISC1, presumably resulting in loss of DISC1 expression. This finding has launched an entire subfield of schizophrenia genetics and neurobiology, with an emphasis on the role of the DISC1 gene product and its protein interaction partners in neurodevelopment and synaptic function (Chubb et al, 2008) .
In the past year, DISC1 has been put into the context of key signal transduction pathways and other genetic findings. In one critical study (Mao et al, 2009) , DISC1 was shown to modulate the 'canonical' Wntsignaling pathway. This pathway (Komiya and Habas, 2008 ) is activated when a member of the Wnt family of secreted glycoproteins binds a member of the Frizzled receptor family along with coreceptors. Pathway activation reduces GSK3b kinase activity, resulting in diminished phosphorylation of b-catenin. Unphosphorylated b-catenin accumulates in the cytoplasm and is translocated into the nucleus, where it functions as a transcriptional coactivator. Among other effects, this transcriptional activity can drive neuronal neurogenesis. DISC1 directly interacts with GSK3b, inhibiting GSK3b phosphorylation of b-catenin and thus increasing b-catenin-induced transcriptional activity. The effect is to mimic Wnt pathway activation. Loss of DISC1 inhibits b-catenin-induced transcription, providing a potential mechanism by which DISC1 loss of function mutations might exert their effect.
DISC1 has also been linked to pathways involving Neuregulin-1 (NRG1), one of the most robust candidate genes for schizophrenia (Mei and Xiong 2008) . Extracellular NRG1, cleaved from Pro-NRG1, interacts with and activates the ErbB family of receptor protein kinases (ErbB2, 3, 4, and EGFR), starting a cascade that activates a number of partially overlapping pathways, including RafF MEK-ERK and PI3K-Akt. NRG1 signaling has been implicated in neuronal migration, axon guidance, synapse formation, myelination, and oligodendrocyte development. NRG-1 activated Akt inhibits GSK3b, tying NRG1 signaling to Wnt and DISC1 activity. The related effects of DISC1 and NRG1 have been highlighted in a zebrafish model, in which DISC1 loss produced developmental deficits very similar to loss of NRG1 signaling, including failure of normal oligodendrocyte development and near total failure of olig2-positive cerebellar neuron development (Wood et al, 2009 ). The effect of psychotropic agents on these pathways provides an additional link to major mental illness. For instance, lithium activates Akt and inhibits GSK3b, whereas antipsychotic agents, by antagonism of D2 receptors, block the stimulatory effect of dopamine on Akt.
Overall, the convergence of genetic, pharmacological, and neurobiological data have opened the door to multiple novel potential therapeutic targets in the DISC1-Wnt-NRG1 systems, and this neurogenetic approach holds considerable promise for future research. For instance, the recent association of the MHC locus on chromosome 6p with schizophrenia (e.g., Stefansson et al, 2009) supports the long standing concept that environmental factors such as infection may have a role in schizophrenia, and provides a rationale for models of disease that encompass both genetic and environmental factors. Associations of neurogranin on 11q24.2 and transcription factor 4 (TCF4) on 18q21.2 with schizophrenia (Stefansson et al, 2009) may lead to new pathways with additional therapeutic targets. Psychiatric research has entered an era in which genetic findings implicate specific signaling pathways, leading to new insights into disease pathogenesis and the development of new approaches to therapeutics. 
